A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Sponsor: Facet Biotech
Terminated
DMC recommendation, no efficacy
Other terminated trials from Facet Biotech
Other Ulcerative Colitis trials with similar outcome
Listed as NCT00279422, this PHASE2/PHASE3 trial focuses on Ulcerative Colitis and remains terminated or withdrawn. Sponsored by Facet Biotech, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Facet Biotech
- PDL BioPharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Amsterdam, Netherlands , Argenti Döme, Hungary , Atlanta, United States , Bedford Park, Australia , Berlin, Germany , Boston, United States , Box Hill, Australia , Brno, Czechia , Budapest, Hungary and 58 more locations